Intracranial Relapse in Pediatric Sarcoma.
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
received:
09
11
2022
accepted:
08
05
2023
medline:
28
9
2023
pubmed:
1
8
2023
entrez:
1
8
2023
Statut:
ppublish
Résumé
Advances in local control techniques, chemotherapy regimens, and imaging modalities have led to improvements in both morbidity and mortality in pediatric sarcoma patients. However, approximately one-third of patients develop disease relapse and intracranial metastasis was considered rare. The incidence of sarcoma brain metastasis is thought to have increased and is associated with grim outcomes. This was a retrospective study of 3 deidentified patient charts illustrating the possibility of the central nervous system as a potential site for pediatric sarcoma relapse and investigate the patterns of such relapses. We note this is the first report of infantile fibrosarcoma brain metastasis and a rare report of sarcoma lymph node metastasis. In addition, each patient was treated with targeted therapies, including entrectinib, Ruxolitnib, and pazopanib. Caregivers in cases 2 and 3 reported new-onset neurological manifestations before identification of new brain metastasis, indicating a lag in detection of new intracranial relapse in asymptomatic sarcoma patients. We suggest implementing a brief review of systems screening tool focused on concerning neurological manifestations to screen for new brain metastasis.
Identifiants
pubmed: 37526369
doi: 10.1097/MPH.0000000000002713
pii: 00043426-990000000-00265
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e810-e816Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Sangkhathat S. Current management of pediatric soft tissue sarcomas. World J Clin Pediatr. 2015;4:94–105.
Choi JH, Ro JY. The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities. Adv Anat Pathol. 2021;28:44–58.
Gaspar N, Hawkins DS, Dirksen U, et al. Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. J Clin Oncol. 2015;33:3036–3046.
Smith HG, Memos N, Thomas JM, et al. Patterns of disease relapse in primary extremity soft-tissue sarcoma. Br J Surg. 2016;103:1487–1496.
Gronchi A, Lo Vullo S, Colombo C, et al. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg. 2010;251:506–511.
Ryzewicz M, McLoughlin HA, Freudenberger C, et al. Unusual metastases from extremity soft tissue sarcomas. Orthopedics. 2008;31:439.
Al Sannaa G, Watson KL, Olar A, et al. Sarcoma Brain Metastases: 28 Years of Experience at a Single Institution. Ann Surg Oncol. 2016;23(Suppl 5):962–967.
Brennan MF, Antonescu CR, Moraco N, et al. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg. 2014;260:416–421; discussion 421-412.
Wang Y, Delisle M, Smith D, et al. Clinical outcomes of brain metastasectomy from soft tissue and bone sarcomas: a systematic review. Int J Clin Oncol. 2022;27:1767–1779.
Ahmad O, Chan M, Savage P, et al. Biology and treatment of metastasis of sarcoma to the brain. Front Biosci (Elite Ed). 2016;8:233–244.
Lucas JT Jr, Colmer HGt, White L, et al. Competing Risk Analysis of Neurologic versus Nonneurologic Death in Patients Undergoing Radiosurgical Salvage After Whole-Brain Radiation Therapy Failure: Who Actually Dies of Their Brain Metastases? Int J Radiat Oncol Biol Phys. 2015;92:1008–1015.
Kokkali S, Vini L, Stergioula A, et al. Brain Metastases from Adult Sarcomas: A Retrospective Cohort Study from the Hellenic Group of Sarcomas and Rare Cancers (HGSRC). J Clin Med. 2021;10:5978.
In GK, Hu JS, Tseng WW. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017;9:533–550.
Gonzalez MR, Bryce-Alberti M, Leon-Abarca JA, et al. Brain Metastases in Patients With Soft-Tissue Sarcomas: Management and Survival-A SEER Population-Based Cohort Study. J Am Acad Orthop Surg Glob Res Rev. 2021;5:e21.00219.
Salvati M, D'Elia A, Frati A, et al. Sarcoma metastatic to the brain: a series of 35 cases and considerations from 27 years of experience. J Neurooncol. 2010;98:373–377.
Chan CM, Lindsay AD, Spiguel AR, et al. Brain metastases from Truncal and extremity bone and soft tissue sarcoma: Single institution study of oncologic outcomes. Rare Tumors. 2020;12:2036361320960060.
Demetri GD, Antonescu CR, Bjerkehagen B, et al. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol. 2020;31:1506–1517.
Barbacid M. On the right TRK: from oncogene discovery to cancer therapeutics. Ann Oncol. 2019;30(Suppl 8):viii3–viii4.
Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731–747.
Sheng WQ, Hisaoka M, Okamoto S, et al. Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues. Am J Clin Pathol. 2001;115:348–355.
Desai AV, Robinson GW, Gauvain K, et al. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022;24:1776–1789.
Lapena LM, Caldas MCS, Ramirez C, et al. Larotrectinib as an Effective Therapy in Congenital Infantile Fibrosarcoma: Report of Two Cases. European J Pediatr Surg Rep. 2022;10:e76–e79.
Shulman DS, DuBois SG. The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers. Paediatr Drugs. 2020;22:189–197.
Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018;378:731–739.
Ziegler DS, Wong M, Mayoh C, et al. Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma. Br J Cancer. 2018;119:693–696.
Liu D, Offin M, Harnicar S, et al. Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Ther Clin Risk Manag. 2018;14:1247–1252.
Ambati SR, Slotkin EK, Chow-Maneval E, et al. Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring ROS1 or ALK Gene Fusions. JCO Precis Oncol. 2018;2(PO):18.00095.
Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21:271–282.
Hong B, Li Y, Yang R, et al. Single-cell transcriptional profiling reveals heterogeneity and developmental trajectories of Ewing sarcoma. J Cancer Res Clin Oncol. 2022;148:3267–3280.
Toomey EC, Schiffman JD, Lessnick SL. Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene. 2010;29:4504–4516.
Pierron G, Tirode F, Lucchesi C, et al. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat Genet. 2012;44:461–466.
Pakos EE, Goussia AC, Tsekeris PG, et al. Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas. Anticancer Res . 2005;25:3591–3596.
Hong JY, Cho HJ, Yun K-H, et al. Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response. Cancer Res Treat. 2023;55:671–683.
Dong Y, Wu W, Kang H, et al. Risk factors of regional lymph node (RLN) metastasis among patients with bone sarcoma and survival of patients with RLN-positive bone sarcoma. Ann Transl Med. 2021;9:48.
Yoshida S, Morii K, Watanabe M, et al. Brain metastasis in patients with sarcoma: an analysis of histological subtypes, clinical characteristics, and outcomes. Surg Neurol. 2000;54:160–164.
Kebudi R, Ayan I, Gorgun O, et al. Brain metastasis in pediatric extracranial solid tumors: survey and literature review. J Neurooncol. 2005;71:43–48.
Yonemoto T, Tatezaki S, Ishii T, et al. Longterm survival after surgical removal of solitary brain metastasis from osteosarcoma. Int J Clin Oncol. 2003;8:340–342.
Meulepas JM, Ronckers CM, Smets A, et al. Radiation Exposure From Pediatric CT Scans and Subsequent Cancer Risk in the Netherlands. J Natl Cancer Inst. 2019;111:256–263.
Morosi C, Bergamaschi L, Livellara V, et al. Relapsing pediatric non-rhabdomyosarcoma soft tissue sarcomas: The impact of routine imaging surveillance on early detection and post-relapse survival. Eur J Cancer. 2022;175:274–281.
Nakamura T, Matsumine A, Matsubara T, et al. Retrospective analysis of metastatic sarcoma patients. Oncol Lett. 2011;2:315–318.
Postovsky S, Barzilai M, Meller I, et al. Does regular follow-up influence the survival of patients with sarcoma after recurrence? The Miri Shitrit pediatric oncology department experience. J Pediatr Hematol Oncol. 2008;30:189–195.
Lin JL, Guillerman RP, Russell HV, et al. Does Routine Imaging of Patients for Progression or Relapse Improve Survival in Rhabdomyosarcoma? Pediatr Blood Cancer. 2016;63:202–205.
Mallebranche C, Carton M, Minard-Colin V, et al. [Relapse after rhabdomyosarcoma in childhood and adolescence: Impact of an early detection on survival]. Bull Cancer Jul-Aug. 2017;104:625–635.
Vaarwerk B, Mallebranche C, Affinita MC, et al. Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience. Cancer. 2020;126:823–831.